COREY WEAVER: Open Payments
NPI 1922586361 · CLIVE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,387 in 90 payments from 21 companies in 2025. Trend: 2023 $624 · 2024 $1,533 · 2025 $3,387
Food & beverage: $2,211Travel & lodging: $1,177
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 8 | $1,825 |
| Otsuka America Pharmaceutical, Inc. | 12 | $196 |
| ABBVIE INC. | 12 | $187 |
| Lundbeck LLC | 7 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $154 |
| E.R. Squibb & Sons, L.L.C. | 10 | $143 |
| Almatica Pharma LLC | 4 | $113 |
| Alkermes, Inc. | 4 | $95 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| Axsome Therapeutics, Inc. | 3 | $75 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, REXULTI, VRAYLAR, CAPLYTA, COBENFY, LOREEV XR, ARISTADA, FANAPT.
Industry payments across IA — which companies pay providers there.
